IGKV2-24: A Potential Drug Target and Biomarker (G28923)

Target Name: IGKV2-24

NCBI ID: G28923

Other Name(s): IGKV224 | immunoglobulin kappa variable 2-24 | Immunoglobulin kappa variable 2-24 | A23

IGKV2-24: A Potential Drug Target and Biomarker

IGKV2-24 is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the IGK family of proteins, which are involved in various cellular processes, including inflammation and stress responses. IGKV2-24 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Drug Target

IGKV2-24 has been shown to play a role in various cellular processes that are involved in disease development and progression. For example, IGKV2-24 has been shown to promote the growth and survival of cancer cells, and it has been used as a potential drug target for cancer treatment. IGKV2-24 has also been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Biomarker

IGKV2-24 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IGKV2-24 has been shown to be abnormally expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that IGKV2-24 may be a useful biomarker for these diseases, and that it may be potential target for drug development.

Expression and Regulation

IGKV2-24 is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the IGK family of proteins, which are involved in various cellular processes, including inflammation and stress responses. IGKV2-24 is regulated by various signaling pathways, including TGF-β, NF-kappa-B, and MAPK/ERK signaling pathways.

IGKV2-24 has been shown to be regulated by several signaling pathways, including TGF-β, NF-kappa-B, and MAPK/ERK signaling pathways. TGF-β signaling is involved in the regulation of cell growth, differentiation, and survival, and is thought to play a role in the development and progression of cancer. NF-kappa-B signaling is involved in the regulation of inflammation and immune responses, and is thought to contribute to the development and progression of autoimmune disorders. MAPK/ERK signaling pathways are involved in the regulation of cell growth, differentiation, and survival, and are thought to play a role in the development and progression of neurodegenerative diseases.

Targeting IGKV2-24

IGKV2-24 has been shown to be a potential drug target for cancer, neurodegenerative diseases, and autoimmune disorders. One approach to targeting IGKV2-24 is to use small molecules or antibodies to inhibit its activity. This can be done by modifying the activity of IGKV2-24 using various techniques, such as site-directed mutagenesis or chemical inhibitors.

Another approach to targeting IGKV2-24 is to use antibodies that recognize and selectively bind to IGKV2-24. This can be done using various techniques, such as affinity purification or yeast two-hybrid assays. Once IGKV2-24 has been targeted, it can be used to study its function and to identify potential drug targets.

Conclusion

IGKV2-24 is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the IGK family of proteins, which are involved in various cellular processes, including inflammation and stress responses. IGKV2-24 has

Protein Name: Immunoglobulin Kappa Variable 2-24

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets